1515. Nationwide trends of invasive pneumococcal disease in Spain for the period 2009-2019

BACKGROUND: Introduction of pneumococcal conjugate vaccines (PCV) is an effective measure to control the invasive pneumococcal disease (IPD) although the emergence of non-vaccine serotypes is of great concern worldwide. METHODS: This study includes national data from IPD cases affecting pediatric and adult population for the period (2009-2019). Data contain 25341 laboratory-confirmed clinical isolates of Streptococcus pneumoniae causing IPD in Spain. RESULTS: The overall reduction of IPD cases by serotypes included in PCV13 was 88% for children and 67% in adults with a constant increase of IPD cases by serotype 8 in adults since 2015. In children, serotypes 24F (12%), 8 (10%) and 3 (9%) were the most frequent in 2019 whereas in adults, serotypes 3 and 8 accounted for 37% of IPD cases. IPD cases in adults by additional serotypes covered by the 23-valent polysaccharide vaccine (PPV23) have risen constantly within the years, increasing from 19% in 2009 to 52% in 2019. IPD cases by Non-vaccine types in adults (not covered by PCV13 or PPV23) show a moderate increase from 14% in 2009 to 24% in 2019. CONCLUSION: Emerging serotypes are observed in Spain with the rise of serotype 24F in children and 8 in adults as a worrisome event. DISCLOSURES: Jose Yuste, n/a, GSK (Consultant)MSD (Consultant, Research Grant or Support)Pfizer (Consultant)